Please login to the form below
Bavarian Nordic
This page shows the latest Bavarian Nordic news and features for those working in and with pharma, biotech and healthcare.
EMA grants Bavarian Nordic access to PRIME scheme for RSV vaccine candidate
Bavarian Nordic has announced that the European Medicines Agency (EMA) has granted access to its priority (PRIME) scheme for the company's vaccine candidate for the prevention of lower respiratory tract ... RSV, Bavarian Nordic’s vaccine candidate, to
Latest news
-
GlaxoSmithKline reportedly looking to sell select antibiotic brands
The Stada deal was just the latest in a string of divestments – in January GSK signed a deal worth up to 955m with Bavarian Nordic to offload its travel vaccines Rabipur
-
Merck’s Ebola vaccine wins approval in four African countries
The latter vaccine is based on Danish biotech Bavarian Nordic’s technology.
-
GSK divests travel vaccines to Bavarian Nordic as part of strategic refocus
Agreed divestment deal is worth up to 955m. GlaxoSmithKline has penned a deal worth up to 955m with Bavarian Nordic, to offload its travel vaccines Rabipur and Encepur.
-
Merck claims first-ever okay for Ebola vaccine, in Europe
Another vaccine – MVA-BN-Filo from Bavarian Nordic – is in late-stage testing in Uganda.
-
J&J catches up to Merck, files Ebola vaccine in Europe
The latter vaccine is based on Danish biotech Bavarian Nordic’s technology.
More from news
Approximately 5 fully matching, plus 21 partially matching documents found.
Latest Intelligence
-
Deal Watch December 2015
200. Bavarian Nordic (DK). Janssen. Collaboration, licence. Vaccine platform technology for development of treatment for cancers induced by HPV.
-
The world is our laboratory
The vaccine regimen, which was discovered in a collaborative research programme with the National Institutes of Health, combines our preventative vaccine with a vaccine from Bavarian Nordic, a biotechnology company based ... Our commitment also included
-
Medius Deal Watch table for March 2015
1, 100. Bavarian Nordic / BMS. Option to license and commercialise.
-
Pharma deals in March 2015
Fortunately, at end 2014 Bavarian Nordic was profitable and had over $175m in cash and an R&D cost of around $85m per year. ... One of Bavarian Nordic's sites is in Martinsried, the biotech cluster near Munich.
-
Deal Watch table for October 2014
Identifying new agents in asthma and COPD. 196. Bavarian Nordic/J&J. Licence and supply.
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Subscribe to our email news alerts
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Manager
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- PMGroup announces launch of new recruitment platform PharmaRole
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- BioNTech reveals plans to spend about €1bn more on research and development this year
- AstraZeneca’s mild combination asthma reliever approved in UK
- Virtual Patient Engagement Program: A Customer Story
- Putting Skin in the Game at AAD 2023
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- MHRA to introduce new UK clinical trials framework
- Sanofi/Regeneron’s Dupixent approved by EC for atopic dermatitis in children
- Inizio appoints Stefanie Christmas as global head of DE&I
- The Considered appoints Bam Zahraie as chief experience officer
PMHub
Innovative Trials
Innovative Trials is a leading global clinical trial patient recruitment company. With over 10 years’ experience, Innovative Trials deploys “boots-on-the-ground”...
Latest intelligence
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
